The Search for Antifungal Prophylaxis After Artificial Corneal Surgery-An In Vitro Study.
Animals
Antibiotic Prophylaxis
Antifungal Agents
/ pharmacology
Aspergillus fumigatus
/ drug effects
Benzalkonium Compounds
/ pharmacology
Candida albicans
/ drug effects
Contact Lenses, Hydrophilic
/ microbiology
Cornea
/ surgery
Drug Combinations
Endophthalmitis
/ microbiology
Eye Infections, Fungal
/ microbiology
Fusarium
/ drug effects
Gatifloxacin
/ pharmacology
Microbial Sensitivity Tests
Polymyxin B
/ pharmacology
Swine
Trimethoprim
/ pharmacology
Journal
Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
10
8
2020
medline:
6
8
2021
entrez:
10
8
2020
Statut:
ppublish
Résumé
To evaluate the antifungal properties of topical antibiotics (already being used successfully to prevent bacterial endophthalmitis) and some promising antiseptics for antifungal prophylaxis in the setting of artificial corneal implantation. Several commonly used antibiotics for antimicrobial prophylaxis after artificial corneal implantation, in addition to antiseptics [benzalkonium chloride (BAK), povidone-iodine (PI), and some ionic liquids (ILs)], were tested in vitro against Candida albicans, Fusarium solani, and Aspergillus fumigatus. The time-kill activity was determined. Toxicity was assayed in vitro on human corneal epithelial cultures using trypan blue. Adhesion and tissue invasion experiments were also carried out on porcine corneas and commonly used contact lenses, with or without gamma irradiation, and by analysis with fluorescence microscopy. Polymyxin B (PMB)/trimethoprim/BAK (Polytrim), PMB alone, gatifloxacin with BAK (Zymaxid), and same-concentration BAK alone exhibited antifungal activity in vitro. Moxifloxacin (MOX) or gatifloxacin without BAK-as well as trimethoprim, vancomycin, and chloramphenicol-had no effect. 1% PI and ILs had the highest efficacy/toxicity ratios (>1), and Polytrim was species dependent. Subfungicidal concentrations of Polytrim reduced adhesion of C. albicans to Kontur contact lenses. Gamma-irradiated corneas showed enhanced resistance to fungal invasion. Of antibiotic preparations already in use for bacterial prophylaxis after KPro surgery, Polytrim is a commonly used antibiotic with antifungal effects mediated by both PMB and BAK and may be sufficient for prophylaxis. PI as a 1% solution seems to be promising as a long-term antifungal agent. Choline-undecanoate IL is effective and virtually nontoxic and warrants further development.
Identifiants
pubmed: 32769678
doi: 10.1097/ICO.0000000000002433
pii: 00003226-202012000-00012
doi:
Substances chimiques
Antifungal Agents
0
Benzalkonium Compounds
0
Drug Combinations
0
Polytrim eyedrops
53320-96-0
Trimethoprim
AN164J8Y0X
Polymyxin B
J2VZ07J96K
Gatifloxacin
L4618BD7KJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1547-1555Références
Durand ML, Dohlman CH. Successful prevention of bacterial endophthalmitis in eyes with the Boston keratoprosthesis. Cornea. 2009;28:896–901.
Odorcic S, Haas W, Gilmore MS, et al. Fungal infections after Boston type 1 keratoprosthesis implantation: literature review and in vitro antifungal activity of hypochlorous acid. Cornea. 2015;34:1599–1605.
Odorcic S, Sabeti S, Haas W, et al. Fungal infections in Boston keratoprosthesis patients: lessons learned and novel developments on the horizon. Semin Ophthalmol. 2016;31:71–84.
Barnes SD, Dohlman CH, Durand ML. Fungal colonization and infection in Boston keratoprosthesis. Cornea. 2007;26:9–15.
Kim MJ, Yu F, Aldave AJ. Microbial keratitis after Boston type I keratoprosthesis implantation: incidence, organisms, risk factors, and outcomes. Ophthalmology. 2013;120:2209–2216.
Mahmoudi S, Masoomi A, Ahmadikia K, et al. Fungal keratitis: an overview of clinical and laboratory aspects. Mycoses. 2018;61:916–930.
Liu MY, Zhang L, Yin XL, et al. Endophthalmitis associated with fungal keratitis and penetrating injuries in North China. Eur J Ophthalmol. 2020;30:455–461.
Iyer G, Srinivasan B, Agarwal S, et al. Keratoprosthesis: current global scenario and a broad Indian perspective. Indian J Ophthalmol. 2018;66:620–629.
White JH, Stephens GM, Cinotti AA. The use of povidone-iodine for treatment of fungi in rabbit eyes. Ann Ophthalmol. 1972;4:855–856.
Apt L, Isenberg S, Yoshimori R, et al. Chemical preparation of the eye in ophthalmic surgery. III. Effect of povidone-iodine on the conjunctiva. Arch Ophthalmol. 1984;102:728–729.
Koerner JC, George MJ, Kissam EA, et al. Povidone-iodine concentration and in vitro killing time of bacterial corneal ulcer isolates. Digit J Ophthalmol. 2018;24:24–26.
Magalhaes FP, do Nascimento HM, Ecker DJ, et al. Microbiota evaluation of patients with a Boston type I keratoprosthesis treated with topical 0.5% moxifloxacin and 5% povidone-iodine. Cornea. 2013;32:407–411.
Pelletier JS, Barone SB, Capriotii JA. Keratoprosthesis prophylaxis: is it time for a paradigm shift? Clin Ophthalmol. 2018;12:1785–1788.
Bergsson G, Arnfinnsson J, Steingrimsson O, et al. In vitro killing of Candida albicans by fatty acids and monoglycerides. Antimicrob Agents Chemother. 2001;45:3209–3212.
Ammendola S, Lembo A, Battistoni A, et al. 10-undecanhydroxamic acid, a hydroxamate derivative of the undecanoic acid, has strong antimicrobial activity through a mechanism that limits iron availability. FEMS Microbiol Lett. 2009;294:61–67.
Petkovic M, Ferguson JL, Gunaratne HQN, et al. Novel biocompatible cholinium-based ionic liquids—toxicity and biodegradability. Green Chem. 2010;12:643–649.
O'Toole GA, Wathier M, Zegans ME, et al. Diphosphonium ionic liquids as broad-spectrum antimicrobial agents. Cornea. 2012;31:810–816.
Agatemor C, Ibsen KN, Tanner EEL, et al. Ionic liquids for addressing unmet needs in healthcare. Bioeng Transl Med. 2018;3:7–25.
Ibsen KN, Ma H, Banerjee A, et al. Mechanism of antibacterial activity of choline-based ionic liquids (CAGE). ACS Biomater Sci Eng. 2018;4:2370–2379.
Behlau I, Martin KV, Martin JN, et al. Infectious endophthalmitis in Boston keratoprosthesis: incidence and prevention. Acta Ophthalmol. 2014;92:e546–e555.
National Committee for Clinical Laboratory Standards. Performance Standard for Antimicrobial Susceptibility Testing. 28th ed. Wayne, PA: Approved Standard M100; 2018.
National Committee for Clinical Laboratory Standards. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. 2nd ed. Wayne, PA: Approved Standard M27-A2; 2002.
Jett BD, Hatter KL, Huycke MM, et al. Simplified agar plate method for quantifying viable bacteria. Biotechniques. 1997;23:648–650.
Gonzalez-Andrades M, Sharifi R, Islam MM, et al. Improving the practicality and safety of artificial corneas: pre-assembly and gamma-rays sterilization of the Boston Keratoprosthesis. Ocul Surf. 2018;16:322–330.
IAEA. Guidelines for Industrial Radiation Sterilization of Disposable Medical Products (Cobalt-60 Gamma Irradiation). IAEA TECDOC Series. Vienna, Austria: International Atomic Energy Agency; 1989.
Fleiszig SM, Zaidi TS, Preston MJ, et al. Relationship between cytotoxicity and corneal epithelial cell invasion by clinical isolates of Pseudomonas aeruginosa. Infect Immun. 1996;64:2288–2294.
Friedlaender MH, Breshears D, Amoozgar B, et al. The dilution of benzalkonium chloride (BAK) in the tear film. Adv Ther. 2006;23:835–841.
Day S, Lalitha P, Haug S, et al. Activity of antibiotics against Fusarium and Aspergillus. Br J Ophthalmol. 2009;93:116–119.
Alfonso E, Miller D, Impact of 4th generation fluoroquinolones on growth rate and detection time of fungal pathogens. Invest Ophthalmol. 2005;46:E-Abstract 2766.
Isenberg SJ, Apt L. The ocular application of povidone-iodine. Commun Eye Health. 2003;16:30–31.
Hughes R, Dart J, Kilvington S. Activity of the amidoamine myristamidopropyl dimethylamine against keratitis pathogens. J Antimicrob Chemother. 2003;51:1415–1418.
Codling CE, Maillard JY, Russell AD. Aspects of the antimicrobial mechanisms of action of a polyquaternium and an amidoamine. J Antimicrob Chemother. 2003;51:1153–1158.
Huang LC, Salvador-Silva M, Leang RS. Correlations of in vitro assays for assessing cytotoxicity and biocompatibility of contact lens multipurpose solutions. Eye Contact Lens. 2018;44(suppl 1):S97–S105.
Islam MM, Sharifi R, Mamodaly S, et al. Effects of gamma radiation sterilization on the structural and biological properties of decellularized corneal xenografts. Acta Biomater. 2019;96:330–344.
Harissi-Dagher M, The role of keratoprosthesis in the treatment of corneal blindness. In: Colby K, Dana R, eds. Foundations of Corneal Disease: Past, Present and Future. Cham, Switzerland: Springer International Publishing; 2020:185–193.
Lanker Klossner B, Widmer HR, Frey F. Nondevelopment of resistance by bacteria during hospital use of povidone-iodine. Dermatology. 1997;195(suppl 2):10–13.
Sivaraman KR, Hou JH, Chang JH, et al. Scanning electron microscopic analysis of biofilm formation in explanted human Boston type I keratoprostheses. Cornea. 2016;35:25–29.
Hoekstra MJ, Westgate SJ, Mueller S. Povidone-iodine ointment demonstrates in vitro efficacy against biofilm formation. Int Wound J. 2017;14:172–179.
Pelletier JS, Capriotti K, Stewart KS, et al. Demodex blepharitis treated with a novel dilute povidone-iodine and DMSO system: a case report. Ophthalmol Ther. 2017;6:361–366.
Ciolino JB, Hudson SP, Mobbs AN, et al. A prototype antifungal contact lens. Invest Ophthalmol Vis Sci. 2011;52:6286–6291.
Dohlman CH, Pavan-Langston D, Rose J. A new ocular insert device for continuous constant-rate delivery of medication to the eye. Ann Ophthalmol. 1972;4:823–832.
Allansmith M, Lee J, McClellan B, et al. Evaluation of a sustained release hydrocortisone ocular insert in humans. Trans Am Acad Ophthalmol Otolaryngol. 1975;79:128.
Robert MC, Frenette M, Zhou C, et al. A drug delivery system for administration of anti-TNF-alpha antibody. Transl Vis Sci Technol. 2016;5:11.
Behlau I, Mukherjee K, Todani A, et al. Biocompatibility and biofilm inhibition of N,N-hexyl,methyl-polyethylenimine bonded to Boston Keratoprosthesis materials. Biomaterials. 2011;32:8783–8796.